Legal pathwaysAnchored 2026-05-02

Can I legally get this peptide where I live?

Sourced jurisdictional information — not legal advice. Pick the peptide and your jurisdiction; Stack returns the current regulatory state with primary-source citations and a route to a licensed clinician.

Awaiting PCAC · Jul 2026
BPC-157 · Texas (US)

Removed from Cat-2 on April 22, 2026. PCAC review scheduled July 23-24, 2026. Not yet legally compoundable.

Removed from Category 2 by the FDA on April 22, 2026 — meaning the FDA no longer flags significant safety concerns — but this is NOT permission to compound. The peptide must clear PCAC review (July 23-24, 2026) and FDA notice-and-comment rulemaking (typically 12-18 months) before licensed 503A pharmacies can legally produce it. As of today, the legitimate-prescription pathway is closed; informal sourcing is research-grey-market and unregulated for human use.

What to do
  1. Track the PCAC July 23-24, 2026 outcome — Stack's /pcac-tracker will publish same-day status updates.
  2. Submit a public comment to the FDA docket (deadline July 9, 2026 for the July meeting).
  3. Discuss with your provider whether an FDA-approved alternative exists for your goal (e.g., Tesamorelin for fat-loss indications).
  4. Do not source from research-use-only vendors based on the April 22 news — that channel remains unregulated.
Jurisdiction context

Texas operates at the federal floor — broader telemedicine prescribing, no additional state-level peptide restrictions beyond federal rules. Currently the friendliest large-state market for compounded peptides.

Sources

Stack publishes sourced regulatory information. We do not provide legal advice for your specific situation, do not endorse research-use-only vendors, and do not substitute for a licensed clinician. Regulatory states change — verify against the cited sources before acting.